Vaccine

Virbac reassesses its 2023 growth and Adjusted EBIT1 forecasts

Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year.…

2 years ago

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for…

2 years ago

NorthX Biologics, a leading Nordic development and manufacturing organisation announces acquisition of a biologics manufacturing unit from Valneva

MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a…

2 years ago

Prevention and Immunization, the Key to Achieve a More Efficient Healthcare System Worldwide

Experts in vaccination from Germany, France and Spain, invited by the Bamberg Foundation, met in Berlin to discuss the key…

2 years ago

Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space

Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab…

2 years ago

Male Plus Founder Tim Torfs on How Stress Affects Performance in the Bedroom

The Belgian Fitness Entrepreneur Dishes on the Pandemic, Stress, and How It Inspired Him to Create Belgium’s First Natural Libido…

2 years ago

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

2 years ago

Emergex Appoints Sir Michael Rake as Board Chairman

Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T…

2 years ago

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

 Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s…

2 years ago